

Confirmed Speakers

Confirmed Plenary Speakers

Discovery of the Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist with Therapeutic Potential in Autoimmune Diseases



Dr Eva CAROFF
(IDORSIA PHARMACEUTICALS LTD, Allschwil, Switzerland)

Electrochemistry in High-Throughput



Dr Nessa CARSON
(ASTRAZENECA, Macclesfield, United Kingdom)

Development of SARS Coronavirus 3CL Protease Inhibitors with an Electrophilic aryl-ketone Warhead



Prof. Yoshio HAYASHI
(TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES, Tokyo, Japan)

Discovery of Novel Microbiome-Sparing Antibiotics with Activity Against Gram-Negative Pathogens



Prof. Paul J. HERGENROTHER
(UNIVERSITY OF ILLINOIS, Urbana, United States)

Title to be Announced



Dr Jean-Baptiste LANGLOIS
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

Leucettinib-21, A DYRK1A Inhibitor Drug Candidate Aiming at the Correction of Cognitive Disorders in People with Down Syndrome or Alzheimer's Disease



Dr Laurent MEIJER
(PERHA PHARMACEUTICALS, Roscoff, France)

Stabilizing Relevant GPCR Conformations to Discover Therapeutic Antibodies



Dr Christel MENET
(CONFO THERAPEUTICS, Brussels, Belgium)

BacPROTACs Mediate Targeted Protein Degradation in Bacteria



Prof. Francesca Ester MORREALE
(THE FRANCIS CRICK INSTITUTE, London, United Kingdom)

Structural Biology Supporting Medicinal Chemistry of Purine Receptors

Confirmed Speakers



Prof. Christa MÜLLER
(UNIVERSITY OF BONN, Bonn, Germany)

Investigating Lysine Acylation Using Chemical Tools



Prof. Christian A. OLSEN
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

Title to be Announced



Dr Christophe PEIXOTO
(GALAPAGOS, Romainville, France)

Fragment-based Design of Methionine Adenosyl Transferase (MAT2a) Inhibitors with Anti-tumour Effect



Dr Marianne SCHIMPL
(ASTRAZENECA, Cambridge, United Kingdom)

2-Oxoglutarate Oxygenases – From Functions to Drugs



Prof. Christopher J. SCHOFIELD
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Title to be Announced



Prof. David SPIEGEL
(YALE UNIVERSITY, New Haven, United States)

Title to be Announced



Dr WEI ZHU
(CHINA INNOVATION CENTER OF ROCHE (CICOR), Shanghai, China)

Confirmed Oral Communications

Discovery of an Oral, Rule-of-5 Compliant, IL-17A Protein-Protein Interaction Modulator (IL-17A PPI_m) for the Treatment of Psoriasis and other Inflammatory Diseases.



Dr Mark D. ANDREWS
(LEO PHARMA, Ballerup, Denmark)

Tackling LysS, A Novel Target to Find New Inhibitors for the Treatment of Tuberculosis

Confirmed Speakers



Dr Laura A.T. CLEGHORN
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

Title to be Announced



Prof. Helena FLORINDO
(IMED - UNIVERSITY OF LISBON, Lisbon, Portugal)

Scaffold out of the Blue: Azulenes for Medicinal Chemistry



Dr Jörg KLEY
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany)

Title to be Announced



Dr Alice LANNE
(ASTRAZENECA, Macclesfield, United Kingdom)

Title to be Announced



Prof. Tetsuo NARUMI
(SHIZUOKA UNIVERSITY, Hamamatsu, Japan)

Unravelling the Potential of the Type 2 Lysophosphatidic Acid Receptor (LPA2) for Central Nervous System Pathologies



Prof. Silvia ORTEGA GUTIERREZ
(UNIVERSIDAD COMPLUTENSE DE MADRID, Madrid, Spain)